Novartis Launches Review Into Safety of Eye Drug Beovu

Source: Reuters

Novartis has launched an external review into the safety of its wet AMD drug Beovu after the American Society of Retinal Specialists (ASRS) raised concerns, according to a Reuters report.

Since Beovu’s approval last October, ASRS has received reports of 14 cases of vasculitis, an inflammation of the blood vessels, of which 11 were designated occlusive retinal vasculitis – a sight-threatening inflammatory eye condition.

Read the full article.

Related Content